Composite butyric acid nanoparticles as well as preparation method and application thereof

By adopting the core-shell structure of composite butyric acid nanoparticles, the targeted colon site delayed release of butyric acid is achieved, which solves the problem of insufficient effectiveness and safety in the treatment of colon inflammation in the prior art, and significantly alleviates osteoporosis .

CN119055618AActive Publication Date: 2024-12-03PEKING UNIV SCHOOL OF STOMATOLOGY +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411561782.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-11-05
Publication Date
2024-12-03
Estimated Expiration
2044-11-05

AI Technical Summary

Technical Problem

Existing intestinal origin bacterial metabolites are limited in effectiveness in the treatment of colon inflammation and have insufficient safety, especially as targeted delivery of drugs cannot be achieved, which may cause systemic toxicity and side effects.

Method used

The core-shell structure of composite butyric acid nanoparticles is adopted, the core is polyvinyl butyric acid nanoparticles, and the shell is shell gel. It is formed by the compound milking method to achieve continuous sustained release of butyric acid to the colon site, improving the therapeutic effect and Security.

Benefits of technology

The composite butyric acid nanoparticles can effectively regulate intestinal microbial homeostasis, reduce pro-inflammatory response, improve the relieving effect of colitis, reduce side effects, and relieve secondary and primary osteoporosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055618A_ABST
    Figure CN119055618A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of polymer compounds, and relates to composite butyric acid nano-particles as well as a preparation method and application thereof. The composite butyric acid nano-particles are of a core-shell structure, the inner core is polyvinyl butyrate nano-particles, and the outer shell is shellac gel. The composite butyric acid nano-particles can target a colon part to realize continuous slow release of butyric acid, and compared with current colitis first-line medicines and butyrate preparations in other forms, the composite butyric acid nano-particles can improve the colitis relieving effect and safety. The homeostasis of intestinal microorganisms can be effectively regulated, the proinflammatory response is down-regulated, and secondary and primary osteoporosis can be relieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of polymer composites, and in particular, relates to composite butyric acid nanoparticles and a preparation method and application thereof. Background Art

[0002] Trillions of microorganisms inhabit the gastrointestinal tract and have co-evolved with their hosts to form mutually beneficial relationships. These symbiotic microorganisms, known as the gut microbiota, regulate host homeostasis in multiple ways. The gut microbiota influences local immune responses in the intestine and contributes to the function of distal organs, including the joints, liver, periodontium, and central nervous system. Therefore, manipulating the microbiome or its functional metabolites may provide opportunities for systemic diseases. Recent studies have demonstrated that probiotics, functional microorganisms, and short-chain fatty acids can positively affect the host by altering the gut microbiota.

[0003] Some existing intestinal bacterial metabolites are used to make dietary supplement preparations, but their effectiveness in treating colon inflammation is limited, their safety is insufficient, and they may cause side effects such as gastrointestinal irritation.

[0004] Butyrate is a short-chain fatty acid with anti-inflammatory properties. The gradual release of butyrate helps to regulate the local intestinal environment, which plays a vital role in regulating the activity and polarization of macrophages. However, it is difficult to achieve effective therapeutic results using only free butyrate because it is impossible to achieve targeted delivery of drugs for treatment and may cause systemic toxicity. Nanotechnology has been used in oral drug delivery systems to further enhance the absorption of drugs by inflamed colonic tissue. Some studies have attempted to address this problem through different formulations, such as polyvinyl butyrate and polymer micelles that release butyrate. However, the polyvinyl butyrate synthesized by Mu et al. was only tested for stability in a constant pH 7.4 solution and was not tested in gastric acid. Wang et al. synthesized two polymer micelles that released butyrate with neutral (NtL-ButM) or negative charge (Neg-ButM), but they only tested the relief of colitis and did not study the effects on other organs in the body. Summary of the invention

[0005] The purpose of the present invention is to provide a composite butyric acid nanoparticle and a preparation method thereof. The composite butyric acid nanoparticle can target the colon to achieve sustained release of butyric acid, and can improve the effect and safety of relieving colitis compared with the current first-line colitis medication and other forms of butyrate preparations. It can effectively regulate intestinal microbial homeostasis and downregulate pro-inflammatory reactions. In addition, the composite butyric acid nanoparticle can also relieve secondary and primary osteoporosis.

[0006] In order to achieve the above-mentioned object, the first aspect of the present invention provides a composite butyric acid nanoparticle, wherein the composite butyric acid nanoparticle is a core-shell structure, wherein the core is polyvinyl butyrate nanoparticles and the shell is shellac gel.

[0007] According to a preferred embodiment of the present invention, the weight ratio of the polyvinyl butyrate nanoparticles to the shellac gel is 0.3-0.6:1.

[0008] The second aspect of the present invention provides a method for preparing the above-mentioned composite butyric acid nanoparticles, comprising the following steps: preparing a polyvinyl butyrate inner core and a shellac outer shell separately, and forming a core-shell structure by a double emulsion method.

[0009] According to a preferred embodiment of the present invention, the method comprises the following steps: (1) under the protection of an inert gas, vinyl butyrate, an initiator and a solvent are mixed to carry out a polymerization reaction to obtain polyvinyl butyrate; a toluene solution of polyvinyl butyrate is mixed with an aqueous liquid of a polyoxyethylene polyoxypropylene ether triblock copolymer and ascorbic acid, and the mixed two phases are stirred at a high speed, subjected to ultrasonic treatment, and stirred overnight to obtain polyvinyl butyrate nanoparticles; (2) mixing a sodium carbonate solution of shellac with gluconolactone to gel, stopping stirring when the liquid becomes completely opaque, centrifuging and discarding the supernatant, collecting the gelatinous shellac and freeze-drying it; (3) Dissolving freeze-dried shellac in a mixed liquid of dichloromethane and methanol to obtain a shellac solution, mixing the shellac solution with a polyvinyl butyrate nanoparticle solution, and subjecting the resulting mixture to ice-bath ultrasonic emulsification to obtain a suspension A; mixing suspension A with a sodium cholate solution, and subjecting the resulting mixture to ice-bath ultrasonic emulsification to obtain a suspension B; adding suspension B dropwise to the sodium cholate solution, stirring at room temperature, to obtain a suspension C; rotary evaporating suspension C to remove dichloromethane, to obtain a suspension D; centrifuging suspension D at room temperature, discarding the supernatant, and resuspending to obtain the composite butyric acid nanoparticles.

[0010] According to a preferred embodiment of the present invention, in step (1), the molar ratio of the vinyl butyrate, the initiator and the solvent is 100-105:1:800-1000; the initiator is azobisisobutyronitrile, and the solvent is acetone; the conditions of the polymerization reaction include: a temperature of 40-60°C and a time of 36-64 hours; after the polymerization reaction is completed, the reaction solution is dialyzed, rotary evaporated and freeze-dried; the concentration of the toluene solution of polyvinyl butyrate is 0.3-0.5 g / mL, the concentration of the polyoxyethylene polyoxypropylene ether triblock copolymer in the aqueous phase system is 4-6% (w / v), and the concentration of ascorbic acid is 4-6 mg / mL.

[0011] According to a preferred embodiment of the present invention, in step (1), the conditions for high-speed stirring include: a rotation speed of 600-1000 rpm and a stirring time of 8-12 min; the conditions for ultrasonic treatment include: a frequency of 10-30 kHz, a power of 10-30 W, and a treatment time of 4-6 min; and the conditions for overnight stirring include: a rotation speed of 200-400 rpm.

[0012] According to a preferred embodiment of the present invention, in step (2), the concentration of the shellac sodium carbonate solution is 70-90 mg / mL; and the mass ratio of shellac to gluconolactone in the shellac sodium carbonate solution is 1:0.6-0.8.

[0013] According to a preferred embodiment of the present invention, in step (3), the concentration of the shellac solution is 4-8 mg / mL; the volume ratio of dichloromethane to methanol in the mixed liquid is 1.5-2.5:1; the volume ratio of the shellac solution to the polyvinyl butyrate nanoparticle solution is 8-12:1; and the concentration of the sodium cholate solution is 0.5-1%.

[0014] The third aspect of the present invention provides the use of the above-mentioned composite butyric acid nanoparticles in the preparation of oral bacterial metabolite preparations.

[0015] The fourth aspect of the present invention provides the use of the composite butyrate nanoparticles in the preparation of colitis drugs or osteoporosis drugs. The osteoporosis includes both secondary osteoporosis and primary osteoporosis.

[0016] Compared with the prior art, the technical advantages of the present invention include: (1) Existing oral bacterial metabolite preparations are absorbed in the upper digestive tract, have poor targeting, and cannot reach the colon and other parts where they need to work. The composite butyrate nanoparticles of the present invention can effectively target the colon and relieve colitis.

[0017] (2) Existing oral bacterial metabolite preparations may cause side effects such as intestinal inflammation after being rapidly released in the digestive tract for a short period of time. The composite butyric acid nanoparticles of the present invention can stay in the colon for a longer time, achieving sustained release of butyric acid.

[0018] (3) Existing oral bacterial metabolite preparations enter the circulatory system after being absorbed in the intestine, which may have adverse effects on other organ systems throughout the body and cause side effects. The composite butyrate nanoparticles of the present invention do not affect the level of butyrate in the circulation, ensuring the biosafety of the material.

[0019] (4) The composite butyrate nanoparticles of the present invention can also alleviate secondary and primary osteoporosis.

[0020] Other features and advantages of the present invention will be described in detail in the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] The above and other objects, features and advantages of the present invention will become more apparent through a more detailed description of exemplary embodiments of the present invention with reference to the accompanying drawings.

[0022] Figure 1 The figure shows the amount of butyric acid released in the supernatant after the composite butyric acid nanoparticles were immersed in gastric fluid simulation fluid (pH 1.5) and intestinal fluid simulation fluid (pH 7.4) for different time periods.

[0023] Figure 2 The zeta potentials of polyvinyl butyrate nanoparticles (BuNP), shellac (Shellac), and composite butyric acid nanoparticles (B@S) are shown.

[0024] Figure 3 The figure shows the retention of polyvinyl butyrate nanoparticles (BuNP) and composite butyric acid nanoparticles (B@S) in the colon after oral administration to mice.

[0025] Figure 4 The colitis score DAI of the blank group (Ctrl group), disease group (DSS group), and treatment groups: oral 5-aminosalicylic acid (5-ASA), free butyrate (Bu), polyvinyl butyrate nanoparticles (BuNP), and composite butyrate nanoparticles (B@S) after dextran sulfate sodium (DSS) was used to induce colitis in mice.

[0026] Figure 5 The results of high-throughput sequencing of 16S rRNA in the cecal feces of mice after dextran sulfate sodium (DSS) induced colitis in mice were shown, including the blank group (Ctrl group), disease group (DSS group), and treatment group: oral 5-aminosalicylic acid (5-ASA), free butyrate (Bu), polyvinyl butyrate nanoparticles (BuNP), and composite butyrate nanoparticles (B@S).

[0027] Figure 6 The results of butyric acid content test in the serum of mice in the disease group (DSS group) and the composite butyric acid nanoparticle treatment group (B@S group) after dextran sulfate sodium (DSS) was used to induce colitis in mice.

[0028] Figure 7 The results show the bone mass of the blank group (Ctrl group), disease group (DSS group), and treatment group: oral 5-aminosalicylic acid (5-ASA), free butyrate (Bu), polyvinyl butyrate nanoparticles (BuNP), and composite butyrate nanoparticles (B@S) after dextran sulfate sodium (DSS)-induced colitis in mice with secondary osteoporosis: (a) micro-CT scan image; (b) quantitative bar graph.

[0029] Figure 8 Shown are the bone mass of the sham group (Sham group), disease group (OVX group), and treatment group: free butyrate (Bu) and composite butyrate nanoparticles (B@S) after bilateral ovariectomy (OVX) induced postmenopausal primary osteoporosis in mice: (a) micro-CT scan image; (b) quantitative bar graph. DETAILED DESCRIPTION

[0030] The preferred embodiments of the present invention will be described in more detail below. Although the preferred embodiments of the present invention are described below, it should be understood that the present invention can be implemented in various forms and should not be limited to the embodiments set forth herein. Example

[0031] A polyvinyl butyrate inner core and a shellac outer shell were prepared separately, and a core-shell structure was formed by a double emulsion method.

[0032] (1) Preparation of polyvinyl butyrate nanoparticles 1) Add vinyl butyrate, azobisisobutyronitrile (AIBN), and acetone (molar ratio 103:1:810) into a three-necked flask, seal it, and blow nitrogen for 30 min.

[0033] 2) After the nitrogen blowing is completed, the flask is transferred to a 50°C water bath for polymerization reaction for 48 h.

[0034] 3) The polymerization solution was dialyzed with methanol for 48 h, and then rotary evaporated and freeze-dried to obtain polyvinyl butyrate.

[0035] 4) Dissolve the prepared polyvinyl butyrate in toluene to a solution concentration of 0.4 g / mL.

[0036] 5) The obtained solution was added to an aqueous phase containing 5% (w / v) Pluronic F-127 and 5 mg / mL ascorbic acid. The two phases were stirred at 800 rpm for 10 min using a high-speed stirrer and then sonicated for 5 min using an ultrasonic probe (20% power, 20 kHz, 20 W).

[0037] 6) Stirring (300 rpm / min) overnight to obtain polyvinyl butyrate nanoparticles (BuNP).

[0038] (2) Preparation of shellac 1) Add 8 g of shellac (concentration 80 mg / mL) to 100 mL of sodium carbonate solution and stir until the solution turns dark purple-black.

[0039] 2) Add 11.5 g of gluconolactone (concentration 115 mg / mL), mix well and allow it to gel.

[0040] 3) Stop stirring when the liquid becomes completely opaque, centrifuge at 4000 rpm for 15 min, discard the supernatant, collect the gel-like shellac, and freeze-dry it for later use.

[0041] (3) Preparation of engineered composite postbiotic nanoparticles 1) Weigh 50 mg of freeze-dried shellac and dissolve it in a mixture of dichloromethane and methanol (volume ratio 5:3) to a final concentration of 6 mg / mL.

[0042] 2) Mix 2 mL of shellac solution with 200 μL of polyvinyl butyrate nanoparticle solution (volume ratio 10:1), and place the mixture in an ice bath ultrasonic emulsification under a 25 W cell disruptor for 3 min to obtain suspension A.

[0043] 3) Suspension A was mixed with 1% sodium cholate solution (volume ratio 1:1), and the mixture was placed in an ice bath ultrasonic emulsification apparatus at 30W for 5 min to obtain suspension B.

[0044] 4) Suspension B was added dropwise into 0.5% sodium cholate solution (volume ratio 2:5), and stirred at room temperature for 10 min to obtain suspension C.

[0045] 5) The suspension C was rotary evaporated for 10 min using a rotary evaporator to remove dichloromethane to obtain a suspension D.

[0046] 6) The suspension D was centrifuged at 11,000 g for 15 min at room temperature, the supernatant was discarded and resuspended in triple distilled water to obtain engineered composite postbiotic nanoparticles (BuNP@Shellac, B@S).

[0047] The butyric acid release in the supernatant of the composite nanoparticles was detected after being immersed in gastric fluid simulation fluid (pH 1.5) and intestinal fluid simulation fluid (pH 7.4) for different time periods. Figure 1 As shown, the material releases less butyric acid in an acidic environment, but can release most of the butyric acid in a weakly alkaline environment, which can achieve better colon targeting and avoid extensive decomposition in gastric acid.

[0048] It can be seen that the formation of a core-shell structure can improve the colon targeting of the material (the colon has a weakly alkaline pH), avoid the material from disintegrating in large quantities in the acidic environment of the stomach, and release butyric acid, which can not only improve the targeting of the material, but also enhance the safety of the material.

[0049] The zeta potential of polyvinyl butyrate nanoparticles (BuNP), shellac (Shellac) and composite butyric acid nanoparticles (B@S) were tested.

[0050] The results are as follows Figure 2As shown: polyvinyl butyrate nanoparticles (BuNP) are positively charged, shellac is negatively charged, and the zeta potential of composite butyric acid nanoparticles (B@S) after forming a core-shell structure changes from positive to negative. According to previous studies, negatively charged drugs are more beneficial in alleviating intestinal inflammation, because positively charged proteins are often enriched in intestinal inflammatory sites, and negatively charged materials are easier to target inflammatory sites.

[0051] Fluorescently labeled polyvinyl butyrate nanoparticles (BuNP) and composite butyric acid nanoparticles (B@S) were gavaged into mice using a gavage needle. The digestive tract of the mice was dissected and isolated 48 hours after gavage, and images of the digestive tract were captured using a small animal imaging system.

[0052] The results are as follows Figure 3 As shown: When using only polyvinyl butyrate nanoparticles (BuNP), their residence time in the intestine is short. After 48 hours, only a small amount of material remains in the colon, the site of drug action, and butyric acid cannot be continuously released to relieve colon inflammation. After forming a core-shell structure, composite butyric acid nanoparticles (BuNP@Shellac) stay in the mouse colon for a longer time. The right picture shows a photo of BuNP@Shellac 48 hours after intragastric administration. A large number of composite butyric acid nanoparticles can still be observed to remain in the colon, which is conducive to the continuous release of butyric acid.

[0053] The colitis score DAI is used to evaluate the severity of colitis by comprehensively evaluating the severity of weight change, diarrhea, and blood in the stool. The higher the score, the more serious the disease. Figure 4 As shown, dextran sulfate sodium (DSS) was used to induce colitis in mice, and it was observed that the DAI score of the disease group (DSS group) was significantly higher than that of the blank group (Ctrl group). After oral administration of 5-aminosalicylic acid (5-ASA, a first-line clinical drug for colitis treatment), free butyrate (Bu), polyvinyl butyrate nanoparticles (BuNP) and composite butyric acid nanoparticles (B@S) to mice with DSS-induced colitis, the severity of colitis was evaluated. It can be found that the B@S material forming a core-shell structure of the present invention can effectively alleviate colitis in mice, and its effect is better than the clinical first-line drug 5-ASA and other forms of butyric acid materials (Bu, BuNP).

[0054] The cecal feces of each group of mice in Test Example 4 were subjected to 16S rRNA microbiome high-throughput sequencing, and the results were as follows: Figure 5 As shown, the intestinal microorganisms of the disease group (DSS group) were significantly changed compared with the blank group (Ctrl group), with a decrease in beneficial microorganisms and an increase in harmful microorganisms. After treatment with different drugs, the use of composite butyrate nanoparticles (BuNP@Shellac) can more effectively regulate the balance of intestinal flora than other treatment groups, restoring the intestinal flora composition to the closest to the blank group.

[0055] The butyric acid content in the serum of mice in the disease group (DSS group) and the composite butyric acid nanoparticle treatment group (B@S group) in Test Example 4 was measured. The results are as follows Figure 6 As shown, it can be found that after treatment with B@S, the butyric acid content in the mouse serum is not significantly different from that in the disease group, indicating that the formation of the core-shell structure will not affect the butyric acid level in the circulation (serum), that is, the butyric acid released by the B@S material only acts in the colon and will not enter the circulation to directly affect the function of other organs, thus ensuring the safety of the material.

[0056] The femurs of the mice in each group in Test Example 4 were scanned by micro-computed tomography (micro-CT) and the femur bone mass was analyzed. The results are as follows: Figure 7 As shown in the figure, the use of dextran sulfate sodium (DSS) can not only induce colitis in mice, but also cause secondary osteoporosis in colitis, which is manifested by a decrease in the percentage of femoral trabecular bone (BV / TV), and the micro-CT three-dimensional reconstruction image also shows that the trabeculae become sparse. After oral administration of 5-aminosalicylic acid (5-ASA, a first-line clinical drug for the treatment of colitis), free butyrate (Bu), polyvinyl butyrate nanoparticles (BuNP) and composite butyric acid nanoparticles (B@S) to mice with DSS-induced colitis secondary osteoporosis, the femoral bone mass was evaluated. It can be found that the B@S material forming a core-shell structure of the present invention can effectively alleviate secondary osteoporosis in mice, and its effect is better than 5-ASA and other forms of butyric acid materials (Bu, BuNP).

[0057] Mice underwent bilateral ovariectomy (OVX) to induce postmenopausal osteoporosis (primary osteoporosis) in mice. The femurs of the sham control group (Sham), disease group (OVX), free butyrate treatment group (Bu) and composite butyrate nanoparticle treatment group (B@S) were scanned by micro-computed tomography (micro-CT) and femoral bone mass analysis was performed. The results are shown in Figure 8 As shown in the figure, bilateral ovariectomy (OVX) can induce osteoporosis in mice, which is manifested by a decrease in the femoral trabecular percentage (BV / TV), and micro-CT three-dimensional reconstruction images also show that the trabeculae become sparse. After oral administration of free butyrate (Bu) and composite butyrate nanoparticles (B@S) to OVX primary osteoporotic mice, the femoral bone mass was evaluated. It can be found that the B@S material forming a core-shell structure of the present invention can effectively alleviate primary osteoporosis in mice, and its effect is better than that of free butyrate.

[0058] The embodiments of the present invention have been described above, and the above description is exemplary, not exhaustive, and is not limited to the disclosed embodiments. Many modifications and changes will be apparent to those skilled in the art without departing from the scope and spirit of the described embodiments.

Claims

1. A composite butyric acid nanoparticle, characterized in that: The composite butyric acid nanoparticles are of a core-shell structure, wherein the core is polyvinyl butyrate nanoparticles and the shell is shellac gel.

2. The composite butyric acid nanoparticles according to claim 1, wherein The weight ratio of the polyvinyl butyrate nanoparticles to the shellac gel is 0.3-0.6:

1.

3. The method for preparing the composite butyric acid nanoparticles according to claim 1 or 2, comprising the following steps: A polyvinyl butyrate inner core and a shellac outer shell were prepared separately, and a core-shell structure was formed by a double emulsion method.

4. The preparation method according to claim 3, wherein The method comprises the following steps: (1) under the protection of an inert gas, vinyl butyrate, an initiator and a solvent are mixed to carry out a polymerization reaction to obtain polyvinyl butyrate; a toluene solution of polyvinyl butyrate is mixed with an aqueous liquid of a polyoxyethylene polyoxypropylene ether triblock copolymer and ascorbic acid, and the mixed two phases are stirred at a high speed, subjected to ultrasonic treatment, and stirred overnight to obtain polyvinyl butyrate nanoparticles; (2) mixing a sodium carbonate solution of shellac with gluconolactone to gel, stopping stirring when the liquid becomes completely opaque, centrifuging and discarding the supernatant, collecting the gelatinous shellac and freeze-drying it; (3) Dissolving freeze-dried shellac in a mixed liquid of dichloromethane and methanol to obtain a shellac solution, mixing the shellac solution with a polyvinyl butyrate nanoparticle solution, and subjecting the resulting mixture to ice-bath ultrasonic emulsification to obtain a suspension A; mixing suspension A with a sodium cholate solution, and subjecting the resulting mixture to ice-bath ultrasonic emulsification to obtain a suspension B; adding suspension B dropwise to the sodium cholate solution, stirring at room temperature, to obtain a suspension C; rotary evaporating suspension C to remove dichloromethane, to obtain a suspension D; centrifuging suspension D at room temperature, discarding the supernatant, and resuspending to obtain the composite butyric acid nanoparticles.

5. The preparation method according to claim 4, wherein In step (1), the molar ratio of vinyl butyrate, initiator and solvent is 100-105:1:800-1000; The initiator is azobisisobutyronitrile, and the solvent is acetone; The polymerization reaction conditions include: temperature of 40-60°C and time of 36-64h; After the polymerization reaction is completed, the reaction solution is dialyzed, rotary evaporated, and freeze-dried; The concentration of the toluene solution of polyvinyl butyrate is 0.3-0.5 g / mL, the concentration of the polyoxyethylene polyoxypropylene ether triblock copolymer in the aqueous phase system is 4-6% (w / v), and the concentration of ascorbic acid is 4-6 mg / mL.

6. The preparation method according to claim 4, wherein In step (1), The high-speed stirring conditions include: a rotation speed of 600-1000 rpm and a stirring time of 8-12 min; The ultrasonic treatment conditions include: frequency 10-30 kHz, power 10-30 W, and treatment time 4-6 min; The overnight stirring conditions include: a rotation speed of 200-400 rpm.

7. The preparation method according to claim 4, wherein In step (2), the concentration of the shellac sodium carbonate solution is 70-90 mg / mL; The mass ratio of shellac to gluconolactone in the shellac sodium carbonate solution is 1:0.6-0.

8.

8. The preparation method according to claim 4, wherein In step (3), the concentration of the shellac solution is 4-8 mg / mL; the volume ratio of dichloromethane to methanol in the mixed liquid is 1.5-2.5:1; The volume ratio of the shellac solution to the polyvinyl butyrate nanoparticle solution is 8-12:1; The concentration of the sodium cholate solution is 0.5-1%.

9. Use of the composite butyric acid nanoparticles according to claim 1 or 2 in the preparation of oral bacterial metabolite preparations.

10. Use of the composite butyric acid nanoparticles according to claim 1 or 2 in the preparation of colitis drugs or osteoporosis drugs.

Citation Information

Patent Citations

  • Feed additive enteric coating butyric acid and preparation method and feed

    CN106107055A